Hypolipidemic activity of HOE-402 is mediated by stimulation of the LDL receptor pathway.
HOE-402 (4-amino-2-[4,4-dimethyl-2-oxo-1-imidazolidinyl]-pyrimidine-5-N- [trifluoromethylphenyl]-carboxamide-monohydrochloride) has been shown to exhibit hypolipidemic action in heterozygous Watanabe heritable hyperlipidemic rabbits. In all animals, elevated cholesterol levels were reduced to normal (from 3.0 to 1.5 mmol/L) after 3 weeks of HOE-402 treatment. This was due entirely to reduction of low density lipoprotein (LDL) cholesterol and was paralleled by accelerated removal of plasma 125I-LDL. This reduction of LDL levels was not found in homozygous LDL receptor-defective animals, emphasizing the necessity of a functional LDL receptor system for the hypolipidemic action. The effect of HOE-402 on LDL receptor activity in the cultured hepatoma cell line HepG2 was also determined. When cells were incubated with plasma from treated animals (containing cholesterol 1.5 mmol/L and HOE-402 80 ng/mL), high-affinity cell-surface binding sites for LDL were induced more than threefold, as shown by Scatchard analysis of cell-surface binding data. Induction of the LDL receptor was detectable after 6 hours and was 300% after 18 hours. This induction was specific for LDL, as 125I-transferrin and [59Fe]transferrin were internalized normally in HOE-402-treated cells. The increase of LDL receptor protein was related to induced LDL receptor mRNA levels (400%), as shown by quantification of Northern blotting experiments. These findings suggest that HOE-402 mediated its hypolipidemic action mainly via the LDL receptor pathway. It enhanced mRNA levels for LDL receptor, hence increasing its synthesis, which subsequently resulted in reduced plasma LDL levels.(ABSTRACT TRUNCATED AT 250 WORDS)
Huettinger
M
M
Department of Medical Chemistry, University of Vienna, Austria.
Hermann
M
M
Goldenberg
H
H
Granzer
E
E
Leineweber
M
M
D000818:Animals; D004705:Endocytosis / Q000502:physiology; D005786:Gene Expression Regulation / Q000187:drug effects; D006579:Heterozygote; D006801:Humans; D006949:Hyperlipidemias / Q000235:genetics; D007093:Imidazoles / Q000494:pharmacology*; D007501:Iron / Q000032:analysis / Q000502:physiology; D008055:Lipids / Q000097:blood*; D008077:Lipoproteins, LDL / Q000032:analysis; D008297:Male; D011743:Pyrimidines / Q000494:pharmacology*; D012333:RNA, Messenger / Q000032:analysis / Q000235:genetics; D011817:Rabbits; D011973:Receptors, LDL / Q000235:genetics / Q000502:physiology*; D014168:Transferrin / Q000032:analysis / Q000502:physiology; D014407:Tumor Cells, Cultured / Q000737:chemistry
D007093:Imidazoles; D008055:Lipids; D008077:Lipoproteins, LDL; D011743:Pyrimidines; D012333:RNA, Messenger; D011973:Receptors, LDL; D014168:Transferrin; C081893:HOE 402; D007501:Iron